Sujal Shah
2013
In 2013, Sujal Shah earned a total compensation of $821.7K as Chief Financial Officer at Cymabay Therapeutics.
Compensation breakdown
| Option Awards | $497,025 |
|---|---|
| Salary | $13,750 |
| Other | $310,900 |
| Total | $821,675 |
Shah received $497K in option awards, accounting for 60% of the total pay in 2013.
Shah also received $13.8K in salary and $310.9K in other compensation.
Rankings
In 2013, Sujal Shah's compensation ranked 7,469th out of 12,286 executives tracked by ExecPay. In other words, Shah earned more than 39.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,469 out of 12,286 | 39th |
Division Manufacturing | 2,688 out of 4,612 | 42nd |
Major group Chemicals And Allied Products | 837 out of 1,462 | 43rd |
Industry group Drugs | 627 out of 1,156 | 46th |
Industry Pharmaceutical Preparations | 496 out of 890 | 44th |
Source: SEC filing on April 21, 2015.
Shah's colleagues
We found two more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2013.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019